Last reviewed · How we verify
ZYNYZ (RETIFANLIMAB-DLWR)
ZYNYZ (generic name: RETIFANLIMAB-DLWR) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by INCYTE CORP. It is currently FDA-approved for Merkel cell carcinoma.
ZYNYZ is an antibody that targets the programmed cell death protein 1 (PD-1) as its molecular mechanism. It is being studied in clinical trials for various types of cancer, including Merkel Cell Carcinoma, Non Small Cell Lung Carcinoma, and Renal Cell Carcinoma.
At a glance
| Generic name | RETIFANLIMAB-DLWR |
|---|---|
| Sponsor | INCYTE CORP |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Target | Programmed cell death protein 1 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Merkel cell carcinoma
Common side effects
- Fatigue
- Peripheral neuropathy
- Nausea
- Alopecia
- Diarrhea
- Musculoskeletal pain
- Constipation
- Hemorrhage
- Rash
- Vomiting
- Decreased appetite
- Pruritus
Serious adverse events
- Serious adverse reactions (overall)
- Sepsis
- Pulmonary embolism
- Diarrhea
- Vomiting
- Immune-mediated enterocolitis
- Warm autoimmune hemolytic anemia
- Hepatitis
- Adrenal insufficiency
- Immune-mediated cholangitis
Key clinical trials
- A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM (Phase 2)
- ctHPVDNA Adapted ChemoRadiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (CHART-AC) (Phase 2)
- PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition (Phase 1)
- Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study (Phase 1)
- A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the (Phase 2)
- A Phase Ib Study of 9-ING-41 (Elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX as Frontline Therapy for Patient (Phase 1)
- UW26001 Phase I/II Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progr (Phase 1)
- A Proof-of-Concept Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Advanced or Metastatic PD-(L)1 Refractory Merk (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZYNYZ CI brief — competitive landscape report
- ZYNYZ updates RSS · CI watch RSS
- INCYTE CORP portfolio CI
Frequently asked questions about ZYNYZ
What is ZYNYZ?
ZYNYZ (RETIFANLIMAB-DLWR) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by INCYTE CORP, indicated for Merkel cell carcinoma.
What is ZYNYZ used for?
ZYNYZ is indicated for Merkel cell carcinoma.
Who makes ZYNYZ?
ZYNYZ is developed and marketed by INCYTE CORP (see full INCYTE CORP pipeline at /company/incyte).
What is the generic name of ZYNYZ?
RETIFANLIMAB-DLWR is the generic (nonproprietary) name of ZYNYZ.
What drug class is ZYNYZ in?
ZYNYZ belongs to the Programmed Death Receptor-1 Blocking Antibody [EPC] class. See all Programmed Death Receptor-1 Blocking Antibody [EPC] drugs at /class/programmed-death-receptor-1-blocking-antibody-epc.
What development phase is ZYNYZ in?
ZYNYZ is FDA-approved (marketed).
What are the side effects of ZYNYZ?
Common side effects of ZYNYZ include Fatigue, Peripheral neuropathy, Nausea, Alopecia, Diarrhea, Musculoskeletal pain. Serious adverse events: Serious adverse reactions (overall), Sepsis, Pulmonary embolism, Diarrhea.
What does ZYNYZ target?
ZYNYZ targets Programmed cell death protein 1 and is a Programmed Death Receptor-1 Blocking Antibody [EPC].
Related
- Drug class: All Programmed Death Receptor-1 Blocking Antibody [EPC] drugs
- Target: All drugs targeting Programmed cell death protein 1
- Manufacturer: INCYTE CORP — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Merkel cell carcinoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing